Switching to everolimus one year after liver transplant
Treatments studied
Part of Brain & nervous system, Digestive system, Genetic & congenital clinical trials.
This trial tests if switching from a standard anti-rejection medicine to everolimus is safe and effective for liver transplant patients. It may help protect kidney function while preventing organ rejection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 79 years old.
- You received a liver transplant at least 1 year ago, but less than 3 years ago.
- You are currently on a calcineurin inhibitor (CNI) anti-rejection medicine.
- You have not taken CNI-free anti-rejection medicines before.
- You have had no rejection episodes in the past 3 years.
- Your liver and kidney function must be adequate (eGFR at least 30 mL/min).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if switching from a standard twice-daily tacrolimus to a once-daily prolonged-release version is safe and effective for liver transplant recipients who have stable liver function. It aims to simplify your medication schedule.
This study tests whether taking immunosuppressive drugs (tacrolimus and mycophenolate mofetil) just once a day, instead of twice, works as well for people who recently had a liver transplant. The goal is to make the medication schedule easier and possibly safer.
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
This trial studies whether everolimus, a transplant medicine, can safely reduce the chance that liver cancer comes back after liver transplant. It compares how well the treatment works while carefully monitoring side effects and safety.
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
Hear when a new Liver Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.